Date: 2016-01-14
Type of information: Financing round
Company: icometrix (Belgium)
Investors: Capricorn ICT Arkiv (Belgium) Annie Vereecken (Biover II) (Belgium) former Cartagenia (now part of Agilent Technologies) CEO Herman Verrels (Belgium) University of Antwerp (Belgium) University of Leuven (Belgium) Antwerp University Hospital (Belgium)
Amount: € 2 million
Funding type: financing round
Planned used: The proceeds will be invested to reach icometrix’ targets for 2016: increasing the use of MSmetrix worldwide, capacitating its branch office in the US, addressing new disease domains, and expanding their business in clinical trials and research studies. Other plans for 2016 include growing the icometrix sales force and development team and moving into a new office.
MSmetrix was developed for Multiple Sclerosis (MS) patients. MSmetrix is a SaaS software to support radiologists and neurologists in the follow-up of Multiple Sclerosis patients. It provides access to reliable measurements on the two main manifestations of MS in the brain, of which small but very significant changes are very difficult to see to the naked eye. Numbers on changes of lesion load and of brain volume over time are represented in an easy online report. The reproducibility of the method is 0.1%, which is lower than the expected brain volume changes for MS patients. The automated measurements by icometrix provide a new piece to the puzzle of personalized patient treatment, complementary to the clinical investigation and radiological report. MSmetrix, received market approval in the EU and other countries including Canada, Brazil and Australia. FDA clearance is pending.
Others: * On January 14, 2016, icometrix announced that the company raised over €2 million additional capital. Investors include Capricorn ICT Arkiv, Annie Vereecken (Biover II), former Cartagenia (now part of Agilent Technologies) CEO Herman Verrelst, and current shareholders, such as the Universities of Antwerp and Leuven and the Antwerp University Hospital. icometrix was founded in 2011 by Dirk Loeckx and Wim Van Hecke. It is a spin-off company of the universities and university hospitals of Leuven and Antwerp. Today, icometrix has grown to a team of over 25 people and is internationally active, with headquarters in Leuven and an office in Boston, USA. They are the worldwide standard in MRI biomarkers in routine clinical practice. Their clinical product, MSmetrix, received market approval in the EU and other countries including Canada, Brazil and Australia. FDA clearance is pending. Furthermore, icometrix is ISO9001 and ISO13485 (Medical Devices) and ISO27001 (Information Security) certified
Therapeutic area: Technology - Services
